XML 28 R18.htm IDEA: XBRL DOCUMENT v3.21.1
Net Loss Per Share
 3 Months Ended
Mar. 31, 2021
Earnings Per Share [Abstract]  
Net Loss Per Share Net Loss Per Share
The following table presents the calculation of basic and diluted net loss per share (in thousands, except share and per share amounts):
Three Months Ended March 31,
20212020
(unaudited)
Numerator:
Net loss$(28,370)$(17,490)
Denominator:
Weighted-average number of shares used in calculating net loss per share, basic and diluted43,870,288 37,108,998 
Net loss per share, basic and diluted$(0.65)$(0.47)

During the three months ended March 31, 2021 and 2020, we incurred net losses and, therefore, the effect of our stock options, restricted stock units, performance-based restricted stock units, convertible senior notes, restricted shares, shares issuable as acquisition-related contingent consideration, and purchase rights committed or shares issued under our employee stock purchase plan were not included in the calculation of diluted net loss per share as the effect would be anti-dilutive.
The following table contains share totals with a potentially dilutive impact:
As of March 31,
20212020
(unaudited)
Common stock options3,344,047 6,640,662 
Restricted stock units2,937,690 2,145,968 
Performance-based restricted stock units307,859 — 
Shares related to convertible senior notes2,768,114 — 
Shares issuable as acquisition-related contingent consideration344,436 — 
Employee stock purchase plan72,892 87,107 
Restricted shares114,747 179,392 
Total potentially dilutive securities9,889,785 9,053,129 

The conversion spread of the Notes will have a potentially dilutive impact when the average market price of our common stock for a given period exceeds the conversion price of $30.60 per share. The shares related to the Notes in the table above are calculated based on the average market price of our common stock for the three months ended March 31, 2021. Capped Calls are excluded from the calculation of diluted earnings per share, as they would be antidilutive.
The shares issuable as acquisition-related contingent consideration in the table above are calculated based on the earn-out achieved and the estimated amount of shares that would be issuable if the contingent consideration liabilities from the acquisitions of Healthfinch and Vitalware were to be settled as of March 31, 2021.